Opinion|Videos|July 29, 2024
How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor
Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.
Advertisement
Video content above is prompted by the following question(s):
- How do you balance the potential clinical benefits of CDK4/6 inhibitors with the cost considerations when making treatment decisions for early breast cancer patients?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Amid SOHO Data, Reviewers of BTK Inhibitors in MCL Call for Trials
2
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
3
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
4
Cross-Trial Vitiligo Data: What Payers Can and Can't Compare
5